Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>Products>This Product

LeadCare® II

Product Image
Product Description

LeadCare® II is the only CLIA-waived, point-of-care lead testing system that makes it possible to test, educate and intervene on-the-spot, in one visit. No need to send patients to an outside lab. No need to re-test due to sample problems at the lab. No risk of losing track of a child who needs treatment.

Who should be tested?

Federal law requires that all Medicaid eligible children be tested at 12 and 24 months and ages 36 to 72 months if they have not previously been tested.

Each state has guidelines for blood lead testing.  The American  Academy of Pediatrics (AAP) recommends that “children should be tested at least once when they are 2 years of age or, ideally, twice, at 1 and 2 years of age, unless lead exposure can be confidently excluded.”4

Contact us for information to help you determine your state’s specific testing requirements.

Who is at risk for lead exposure? Children are considered at risk if any of the following are true4:
•    Child lives in or frequently visits a home built before 1950, or a recently renovated home built before 1978
•    Child has a sibling or frequent playmate with elevated blood lead levels
•    Child's parent or primary caregiver works with lead. Examples include: battery recycling or manufacture, lead smelting, lead mining, auto repair, shipbuilding, construction, plumbing, and glass manufacture5
•    Child is a recent immigrant, refugee, or foreign adoptee.
•    Child has a household member who uses traditional, folk, or ethnic remedies or cosmetics or who routinely eats food imported informally (e.g., by a family member)

No safe levels. Evidence continues to grow that blood lead levels as low as 5 ug/dL may impair cognition3, with no minimum threshold yet identified.

Lifelong consequences of lead exposure include:
•    Six times higher likelihood of having a reading disability6
•    Being seven times more likely to drop out of high school6
•    Lower scores on neurobehavioral development7
•    Lower scores on tests for math, reading, nonverbal reasoning and short term memory7
•    Hypertension that contributes to adult cardiovascular disease8
•    Decline in IQ with every 1.0 μg/dL increase in blood lead9

Early diagnosis helps to quickly address the effects of lead exposure and provides impetus for lead abatement in homes.

LeadCare II is the only CLIA-waived point-of-care blood lead testing system. Employees of an office or lab operating under a CLIA Certificate of Waiver can administer the test.

Product LeadCare® II
Company Magellan Diagnostics
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Magellan Diagnostics
101 Billerica Ave, Building 4 North Billerica, MA 01862 USA

Tel: +1 800-959-5095
Fax: +1 800-755-5095

Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos